CL2016002508A1 - Uso de un compuesto correspondiente a 5-4-2-5-1-hidroxietil-2-piridiniletoxibencil-2,4-tiazolidindiona, para el tratamiento o prevención de un trastorno del sistema nervioso central, seleccionado de una enfermedad neurodegenerativa, enfermedad cerebrovascular, enfermedad neuroinflamatoria, entre otras. - Google Patents
Uso de un compuesto correspondiente a 5-4-2-5-1-hidroxietil-2-piridiniletoxibencil-2,4-tiazolidindiona, para el tratamiento o prevención de un trastorno del sistema nervioso central, seleccionado de una enfermedad neurodegenerativa, enfermedad cerebrovascular, enfermedad neuroinflamatoria, entre otras.Info
- Publication number
- CL2016002508A1 CL2016002508A1 CL2016002508A CL2016002508A CL2016002508A1 CL 2016002508 A1 CL2016002508 A1 CL 2016002508A1 CL 2016002508 A CL2016002508 A CL 2016002508A CL 2016002508 A CL2016002508 A CL 2016002508A CL 2016002508 A1 CL2016002508 A1 CL 2016002508A1
- Authority
- CL
- Chile
- Prior art keywords
- disease
- disorder
- hydroxyethyl
- prevention
- treatment
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 208000035475 disorder Diseases 0.000 title abstract 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 title abstract 2
- 208000026106 cerebrovascular disease Diseases 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 210000003169 central nervous system Anatomy 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 238000013024 troubleshooting Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382130 | 2014-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002508A1 true CL2016002508A1 (es) | 2017-04-21 |
Family
ID=50513194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002508A CL2016002508A1 (es) | 2014-04-02 | 2016-10-03 | Uso de un compuesto correspondiente a 5-4-2-5-1-hidroxietil-2-piridiniletoxibencil-2,4-tiazolidindiona, para el tratamiento o prevención de un trastorno del sistema nervioso central, seleccionado de una enfermedad neurodegenerativa, enfermedad cerebrovascular, enfermedad neuroinflamatoria, entre otras. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9782395B2 (OSRAM) |
| EP (2) | EP3388064B1 (OSRAM) |
| JP (2) | JP6745726B2 (OSRAM) |
| KR (1) | KR102418167B1 (OSRAM) |
| CN (1) | CN106470991B (OSRAM) |
| AU (1) | AU2015239112C1 (OSRAM) |
| CA (1) | CA2943373C (OSRAM) |
| CL (1) | CL2016002508A1 (OSRAM) |
| CY (2) | CY1120454T1 (OSRAM) |
| DK (2) | DK3388064T3 (OSRAM) |
| EA (2) | EA202091120A3 (OSRAM) |
| ES (2) | ES2678046T3 (OSRAM) |
| HR (2) | HRP20180983T1 (OSRAM) |
| HU (2) | HUE055351T2 (OSRAM) |
| IL (1) | IL248037B (OSRAM) |
| LT (2) | LT3125888T (OSRAM) |
| MX (1) | MX373234B (OSRAM) |
| NZ (1) | NZ725492A (OSRAM) |
| PL (2) | PL3388064T3 (OSRAM) |
| PT (2) | PT3388064T (OSRAM) |
| SG (1) | SG11201608218QA (OSRAM) |
| SI (2) | SI3125888T1 (OSRAM) |
| WO (1) | WO2015150476A1 (OSRAM) |
| ZA (1) | ZA201607286B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| AU2014236510A1 (en) * | 2013-03-14 | 2015-09-24 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| DK3388064T3 (da) * | 2014-04-02 | 2021-04-19 | Minoryx Therapeutics S L | 2,4-thiazolidindionderivater i behandling af forstyrrelse i centralnervesystemet |
| KR102595034B1 (ko) | 2016-12-01 | 2023-10-26 | 미노릭스 테라퓨틱스 에스.엘. | 비알코올성 지방간 질환을 치료하기 위한 5-[[4-[2-[5-(1-하이드록시에틸)피리딘-2-일]에톡시]페닐]메틸]-1,3-티아졸리딘-2,4-디온 |
| LT3559010T (lt) * | 2016-12-23 | 2022-10-10 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hidroksietil)-2-piridinil]etoksi]fenil]metil]-2,4-tiazolidindiono ir jo druskų gavimo būdas |
| KR20210031435A (ko) | 2018-06-06 | 2021-03-19 | 미노릭스 테라퓨틱스 에스.엘. | 치료학적 유효량의 5-[[4-[2-[5-(1-히드록시에틸)피리딘-2-일]에톡시]페닐]메틸]-1,3-티아졸리딘-2,4-디온을 투여하는 방법 |
| US20210228558A1 (en) * | 2018-06-06 | 2021-07-29 | Minoryx Therapeutics S.L. | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts |
| SI3801515T1 (sl) | 2018-06-06 | 2025-07-31 | Minoryx Therapeutics S.L. | 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion in soli za uporabo pri zdravljenju mitohondrijske bolezni |
| MX2022013021A (es) | 2020-04-30 | 2023-01-16 | Minoryx Therapeutics S L | Leriglitazona para tratar inflamacion pulmonar y enfermedad pulmonar intersticial. |
| US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
| US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
| WO2024141951A1 (en) | 2022-12-28 | 2024-07-04 | Minoryx Therapeutics S.L. | Optimized dosing of leriglitazone |
| WO2024231881A2 (en) | 2023-05-09 | 2024-11-14 | Minoryx Therapeutics S.L. | Polymorphic forms and formulations of leriglitazone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441971A (en) | 1991-04-11 | 1995-08-15 | The Upjohn Company | Thiazolidinedione derivatives, production and use thereof |
| CA2106967C (en) * | 1991-04-11 | 2003-12-09 | Takashi Sohda | Thiazolidinedione derivatives, production and use thereof |
| WO1993022445A1 (en) * | 1992-05-05 | 1993-11-11 | The Upjohn Company | A process for producing pioglitazone metabolite |
| US5952509A (en) | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
| US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| ATE319449T1 (de) | 2001-12-21 | 2006-03-15 | Smithkline Beecham Corp | Dosierschema für ppar-gamma-aktivatoren |
| US8993773B2 (en) | 2002-07-16 | 2015-03-31 | Cadila Healthcare Limited | Process to prepare pioglitazone via several novel intermediates |
| AU2003254146A1 (en) * | 2003-07-24 | 2005-03-07 | Case Western Reserve University | Methods for the treatment of parkinson's disease |
| RU2445957C2 (ru) * | 2006-03-16 | 2012-03-27 | Метаболик Солюшнз Девелопмент Компани | Аналоги тиазолидиндиона |
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| NZ600421A (en) * | 2009-12-15 | 2014-06-27 | Metabolic Solutions Dev Co Llc | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases |
| US8895536B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating chronic inflammation and inflammatory diseases |
| US20150224120A1 (en) | 2011-09-14 | 2015-08-13 | Catherine Clelland | Compositions and methods for treating hyperprolinemia-associated mental disorders |
| US8865747B2 (en) * | 2012-03-23 | 2014-10-21 | Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) | Pioglitazone for use in the treatment of adrenoleukodystrophy |
| US20140178456A1 (en) | 2012-08-30 | 2014-06-26 | Udaya Sankar Devanaboyina | Methods and compositions for treating type 2 diabetes and related conditions |
| AU2014236510A1 (en) | 2013-03-14 | 2015-09-24 | Deuterx, Llc | Deuterium-enriched 2,4-thiazolidinediones and methods of treatment |
| US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| DK3388064T3 (da) * | 2014-04-02 | 2021-04-19 | Minoryx Therapeutics S L | 2,4-thiazolidindionderivater i behandling af forstyrrelse i centralnervesystemet |
-
2015
- 2015-04-01 DK DK18173541.6T patent/DK3388064T3/da active
- 2015-04-01 EA EA202091120A patent/EA202091120A3/ru unknown
- 2015-04-01 WO PCT/EP2015/057224 patent/WO2015150476A1/en not_active Ceased
- 2015-04-01 CA CA2943373A patent/CA2943373C/en active Active
- 2015-04-01 HU HUE18173541A patent/HUE055351T2/hu unknown
- 2015-04-01 EP EP18173541.6A patent/EP3388064B1/en active Active
- 2015-04-01 ES ES15713499.0T patent/ES2678046T3/es active Active
- 2015-04-01 SI SI201530325T patent/SI3125888T1/en unknown
- 2015-04-01 JP JP2016560727A patent/JP6745726B2/ja active Active
- 2015-04-01 AU AU2015239112A patent/AU2015239112C1/en active Active
- 2015-04-01 SG SG11201608218QA patent/SG11201608218QA/en unknown
- 2015-04-01 HU HUE15713499A patent/HUE039555T2/hu unknown
- 2015-04-01 LT LTEP15713499.0T patent/LT3125888T/lt unknown
- 2015-04-01 HR HRP20180983TT patent/HRP20180983T1/hr unknown
- 2015-04-01 EA EA201691997A patent/EA035866B1/ru unknown
- 2015-04-01 PT PT181735416T patent/PT3388064T/pt unknown
- 2015-04-01 DK DK15713499.0T patent/DK3125888T3/en active
- 2015-04-01 ES ES18173541T patent/ES2872335T3/es active Active
- 2015-04-01 EP EP15713499.0A patent/EP3125888B1/en active Active
- 2015-04-01 PL PL18173541T patent/PL3388064T3/pl unknown
- 2015-04-01 PL PL15713499T patent/PL3125888T3/pl unknown
- 2015-04-01 CN CN201580018404.6A patent/CN106470991B/zh active Active
- 2015-04-01 NZ NZ725492A patent/NZ725492A/en unknown
- 2015-04-01 KR KR1020167030649A patent/KR102418167B1/ko active Active
- 2015-04-01 PT PT157134990T patent/PT3125888T/pt unknown
- 2015-04-01 MX MX2016012687A patent/MX373234B/es active IP Right Grant
- 2015-04-01 LT LTEP18173541.6T patent/LT3388064T/lt unknown
- 2015-04-01 SI SI201531591T patent/SI3388064T1/sl unknown
-
2016
- 2016-05-05 US US15/147,484 patent/US9782395B2/en active Active
- 2016-09-26 IL IL248037A patent/IL248037B/en active IP Right Grant
- 2016-10-03 CL CL2016002508A patent/CL2016002508A1/es unknown
- 2016-10-21 ZA ZA2016/07286A patent/ZA201607286B/en unknown
-
2017
- 2017-10-05 US US15/725,950 patent/US10179126B2/en active Active
-
2018
- 2018-07-23 CY CY20181100765T patent/CY1120454T1/el unknown
- 2018-12-13 US US16/218,829 patent/US20190255032A1/en not_active Abandoned
-
2020
- 2020-05-07 JP JP2020081949A patent/JP2020117539A/ja active Pending
-
2021
- 2021-03-30 HR HRP20210518TT patent/HRP20210518T1/hr unknown
- 2021-04-27 CY CY20211100363T patent/CY1124088T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002508A1 (es) | Uso de un compuesto correspondiente a 5-4-2-5-1-hidroxietil-2-piridiniletoxibencil-2,4-tiazolidindiona, para el tratamiento o prevención de un trastorno del sistema nervioso central, seleccionado de una enfermedad neurodegenerativa, enfermedad cerebrovascular, enfermedad neuroinflamatoria, entre otras. | |
| MX2018016331A (es) | Formas cristalinas de compuesto de triazolopirimidina. | |
| DOP2017000149A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
| CO2017005959A2 (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| CL2016002573A1 (es) | Compuesto de ciclopropanamina y sus usos. | |
| CR20150364A (es) | Compuesto heterociclico | |
| CL2017001126A1 (es) | Agentes inmunoreguladores | |
| CO2017000065A2 (es) | Indoles funcionalizados y sustituidos como agentes anti-cáncer | |
| MX2018012655A (es) | Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares. | |
| DOP2018000040A (es) | 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| MX377534B (es) | Compuestos para usarse en el tratamiento de hiperinsulinemia. | |
| GT201700090A (es) | Alcoholes trifluorometílicos como moduladores de roryt | |
| CL2018001502A1 (es) | Procedimiento para el tratamiento de efluente acuoso. | |
| UY37980A (es) | Compuestos novedosos para tratar enfermedades parasitarias | |
| UY36081A (es) | Compuestos inhibidores de metaloenzima como fungicidas. | |
| ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
| MX2019002607A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. | |
| CL2016001745A1 (es) | Ácido (s)-3'-metil-abscísico y ésteres del mismo | |
| AR099300A1 (es) | Hexahidrofuropirroles como inhibidores de pde1 | |
| LT3356337T (lt) | Tricikliniai dibenzotiazepino tipo junginiai, skirti cdkl5 sutrikimų gydyme | |
| ITUA20161522A1 (it) | Composto nutraceutico per il trattamento del decadimento cognitivo | |
| ES1178759Y (es) | Dispositivo para el tratamiento de la epilepsia | |
| ES1180258Y (es) | Util para el tratamiento del estuco sintetico |